WHO backs restriction of Regeneron's REGEN-COV for Omicron patients
domoskanonos/iStock via Getty Images


The World Health Organization in its updated guidelines recommended Regeneron Pharmaceuticals' (NASDAQ:REGN) COVID-19 antibody cocktail REGEN-COV (casirivimab- imdevimab) only for people who are not infected with Omicron as evidence suggested that the therapy was ineffective against the variant.
WHO said it now recommends that the therapy only given when the infection is caused by another variant.
In January, the FDA had also restricted the use of the treatment citing lack of efficacy against Omicron variant.